AIM ImmunoTech Inc is trading 5.1% down at $0.39 in pre-market, extending heavy losses following a sharp dilution-driven collapse.
- The company recently issued significant equity and warrants to regain NYSE American compliance, which triggered an approximate 85% plunge and substantial shareholder dilution.
- Selling pressure remains elevated as investors continue to react to the capital structure changes, despite a relatively calm broader market backdrop.